

SMEs go LifeSciences – Potential partners with a project ideas

BioLog Technologies – Israel	<i>Projects # 75, 76, 77</i>
Spectrum Dynamics - Israel	<i>Project # 80</i>
Skuld-Tech – France	<i>Project # 108</i>
Yeditepe University - Turkey	<i>Project # 115</i>
Aurora Fine Chemicals Ltd - Austria	<i>Project #116</i>

Project #75

Project #75 - BioLog Technologies - Israel

Date: 2005/05/11	Deadline: 2006/12/31
------------------	----------------------

Contact

Organisation	BioLog Technologies	Department	
Contact person	Chema, Dr. Doron		
Email	doron@biolog-tech.com		
Address	Hagavish 4A, P.O. Box 8027		
Postcode	42101	City	Netaniya
Country	Israel		
Telephone	+972-52-222977	Fax	+972-9-8851090
Website	www.biolog-tech.com		

Familiar with the European Framework Programme? **YES**

PROJECT

Title: Improved design of more effective drugs	Acronym: Genomic based drugs
---	-------------------------------------

Project type	STREP
Status	Planned for submission
Call references	Call 4th

Priorities' Main Research Areas	Life Science genomics and biotechnology for health
--	--

Workprogramme Topic (according to each priority workprogramme)	LSH-2005-1.2.1-3: Rational and accelerated development of new, safer, more effective drugs including pharmacogenomics approaches
--	--

Project description	This project is aimed to design better and safer drugs, based on genomic information. BioLogs' flexible and highly adaptive computational technology which integrates bioinformatics with Chemoinformatics enables in-depth exploration of molecular libraries according to various molecular properties, in respect to the target proteins families and to a desired ADME/Tox profile.
----------------------------	---

Keywords	Drug discovery, genomic information, ADME, virtual libraries, small molecules
-----------------	---

Partners already involved	
----------------------------------	--

Project budget (for the running projects)	nc	Budget reserved for SMEs	nc
--	----	---------------------------------	----

Research topics

- LSH-2005-1.2.1-3: Rational and accelerated development of new, safer, more effective drugs including pharmacogenomics approaches - STREPs dedicated to SMEs

Profile of SME sought

Role	technology development, research
Country /region	Any
Start of partnership	start-up phase
Expertise required	Small molecules synthesis capabilities ADME/Tox screening capabilities Screening capabilities in-vitro and/or in-vivo Databases of ADME and Toxicology data companies which specialized in Genomic data

Project #76

Project #76 - BioLog Technologies - Israel

Date: 2005/05/11	Deadline: 2006/12/31
------------------	----------------------

Contact

Organisation	BioLog Technologies	Department	
Contact person	Chema, Dr. Doron		
Email	doron@biolog-tech.com		
Address	Hagavish 4A, P.O. Box 8027		
Postcode	42101	City	Netaniya
Country	Israel		
Telephone	+972-52-222977	Fax	+972-9-8851090
Website	www.biolog-tech.com		

Familiar with the European Framework Programme? **YES**

PROJECT

Title: High throughput protein structure determination	Acronym: protein-structure-prediction
---	--

Project type	Integrated Project
Status	Planned for submission
Call references	Call 4th

Priorities' Main Research Areas	Life Science genomics and biotechnology for health
Workprogramme Topic (according to each priority workprogramme)	LSH-2005-1.1.2-1: Structural genomics interdisciplinary initiative

Project description

The project is aimed to develop approaches for high-throughput determination of protein structure involving experimentally and bioinformatics approaches. BioLog has a unique, highly flexible computational platform technology which can be used to design and implement different algorithmic solutions which are adapted to different type of protein families.

Keywords	Protein structure prediction, nmr, x-ray, high-throughput		
Partners already involved			
Project budget (for the running projects)	nc	Budget reserved for SMEs	nc

Research topics

- LSH-2005-1.1.2-1: Structural genomics interdisciplinary initiative - INTEGRATED PROJECT.

Profile of SME sought

Role	technology development, research
Country /region	Any
Start of partnership	start-up phase
Expertise required	Expression of proteins Experimental determination of protein structure (X-ray, Nmr)

Project #77

Project #77 - BioLog Technologies - Israel

Date: 2005/05/11	Deadline: 2006/12/31
------------------	----------------------

Contact

Organisation	BioLog Technologies	Department	
Contact person	Chema, Dr. Doron		
Email	doron@biolog-tech.com		
Address	Hagavish 4A, P.O. Box 8027		
Postcode	42101	City	Netaniya
Country	Israel		
Telephone	+972-52-222977	Fax	+972-9-8851090
Website	www.biolog-tech.com		

Familiar with the European Framework Programme? **YES**

PROJECT

Title: Improved design of more effective drugs	Acronym: drug design
---	-----------------------------

Project type	STREP
Status	Planned for submission
Call references	Call 4th

Priorities' Main Research Areas	Life Science genomics and biotechnology for health
Workprogramme Topic (according to each priority workprogramme)	LSH-2005-2.2.0-8: Small-ligand libraries: improved tools for exploration and prospective anti-tumor therapy

Project description

This project is aimed to improve the design of small ligand libraries in order to achieve better anti tumour therapy. BioLogs' flexible and highly adaptive computational technology which integrates bioinformatics with Chemoinformatics enables in-depth exploration of molecular libraries according to various molecular properties, in respect to the target proteins families and to a desired ADME/Tox profile.

Keywords

Drug discovery, genomic information, ADME, virtual libraries, small molecules

Partners already involved
Project budget (for the running projects)

nc

Budget reserved for SMEs

nc

Research topics

- LSH-2005-2.2.0-8: Small-ligand libraries: improved tools for exploration and prospective anti-tumor therapy - STREPs dedicated to SMEs

Profile of SME sought

Role	technology development, research
Country /region	Any
Start of partnership	start-up phase
Expertise required	Small molecules synthesis capabilities ADME/Tox screening capabilities Screening capabilities against tumours models in vitro and/or in-vivo Databases of ADME and Toxicology data

Project #80

Project #80 - Spectrum Dynamics - Israel

Date: 2005/06/02	Deadline: 2006/12/31
------------------	----------------------

Contact

Organisation	Spectrum Dynamics	Department	Clinical Affairs
Contact person	Dickman, Ms. Dalia		
Email	daliad@spectrum-dynamics.com		
Address	2 Haetgar Street, Carmel Building, P.O. Box 2026		
Postcode	39120	City	Tirat HaCarmel
Country	Israel		
Telephone	+972-4-858-0774	Fax	+972-4-858-0776
Website	www.spectrum-dynamics.com		

Familiar with the European Framework Programme? **YES**

PROJECT

Title: Nuclear (Molecular) Imaging of Breast Cancer ; Transrectal nuclear (molecular) imaging of primary prostate cancer for early detection	Acronym: Breast Nuclear Imaging ; Prostate nuclear imaging
Project type	STREP
Status	Planned for submission
Call references	Call 4th
Priorities' Main Research Areas	Life Science genomics and biotechnology for health
Workprogramme Topic (according to each priority workprogramme)	LSH-2005-2.2.0-9: Improving resolution of current imaging devices relevant to cancer diagnosis and therapy

Project description

Breast cancer is the leading cause of cancer death among women worldwide with one of eight women developing breast cancer some time during her life. Breast cancer is widely screened with mammography every 1-2 years in women aged 40 and older. While mammography is a well-established technique and has widespread clinical acceptance, the sensitivity of mammography is 85% and decreases to <70% in patients with dense breasts. In addition, mammography has a low specificity of 20-35% leading to a large number of unnecessary biopsies and consequently, the formation of radio dense scar tissue contributing to uncertainties in future mammography scans.

At least 25% of women have dense breasts which are difficult to image radiographically. Scintimammography (nuclear imaging of the breast) is a beneficial adjunct for breast cancer diagnosis given that its accuracy is not affected by breast density. Despite this, scintimammography has not been well adopted in the radiology community due to technological and ergonomical limitations associated with conventional gamma cameras. While a sensitivity of 85% and a specificity of 87% may be achieved in lesions >10mm, the sensitivity significantly decreases with lesions <10mm.

Spectrum Dynamics' BroadView™ core technology will be employed in a product tailored for scintimammography that will provide the same familiar views as standard mammography. Spectrum Dynamics technology provides the increased sensitivity and resolution required to image tumors as small as 3mm in size. By providing a system with high sensitivity and mammography compatible views, nuclear imaging of the breast should be easily accepted as an adjunct for all patients with positive mammography findings. This, in turn, would potentially significantly decrease the number of patients sent to biopsy resulting in a potential annual savings to the healthcare payer industry ranging from \$189 Million-\$420 Million.

Keywords	Functional Molecular Imaging; Scintimammography; Breast Cancer Diagnosis		
Partners already involved	N/A		
Project budget (for the running projects)	nc	Budget reserved for SMEs	nc

Research topics

- LSH-2005-2.2.0-9: Improving resolution of current imaging devices relevant to cancer diagnosis and therapy - STREPs dedicated to SMEs

Profile of SME sought

Role	technology development, demonstration
Country /region	Any
Start of partnership	start-up phase
Expertise required	Breast cancer-specific molecular tracer development; Radiologist/ Nuclear Medicine Specialist.

Project #108

Project #108 - France

Date: 2005/06/23	Deadline: 2005/12/31
------------------	----------------------

Contact

Partner search located in France

To obtain more information about this Partner Search, feel free to contact our national expert in charge of this file:

Organisation	CR 22 / ANVAR - Agence Nationale de Valorisation de la Recherche		
Official Representant	GANOOTE, Mr Michel		
Expert	DIEVAL, Ms Annabelle		
Email	adieval@anvar.fr		
Address	27-31 Avenue du Général Leclerc		
Postcode	F-94710	City	MAISONS ALFORT CEDEX
Country	France		
Website	www.anvar.fr		
Telephone	+33-1-41 79 94 99	Fax	+33-1-49 24 96 21

Familiar with the European Framework Programme? **YES**

PROJECT

Title: project title to be defined	Acronym:
---	-----------------

Project type	SME STREP
Status	Planned for submission
Call references	Call 4th

<p>Priorities' Main Research Areas</p>	<p>1.B. APPLICATION OF KNOWLEDGE AND TECHNOLOGIES IN THE FIELD OF GENOMICS AND BIOTECHNOLOGY FOR HEALTH 1.B.1. Rational and accelerated development of new, safer, more effective drugs including pharmacogenomics approaches 1.B.2. Development of new diagnostics 1.B.5. Innovative research in post-genomics, which has high potential for application</p> <p>2.B. CANCER 2.B.1. COMBATING CANCER</p>
<p>Workprogramme Topic (according to each priority workprogramme)</p>	<p>-Rational and accelerated development of new, safer, more effective drugs including pharmaco-genomics approaches -Development of new diagnostics -Innovative research in post-genomics, which has high potential for application -Innovative technological approaches for cancer therapy</p>

Project description

The principal objective of this research is to identify a palette of gene expression changes associated with the biologic disturbances unique to doping. These changes could be used to detect and thereby deter athletes from using any of the plethora of agents capable for instance of increasing the oxygen carrying capacity of their blood. The goal is to provide antidoping authorities with a single test capable of detecting use of any of the spectrum of agents. Moreover this strategy and the enhanced understanding of gene expression changes offers promise as a platform for investigating the potential for such markers to detect gene doping.

Our company is a biotechnology company focused on functional genomics. Its mission is to :

- select and validate biomarkers leading to design new diagnosis,
- identify new targets,
- generate new leads for biopharmaceutical companies and tailors treatment.

Skuld-Tech platform is focused on existing molecules/drugs repositioning and therapies optimisation especially in oncology and haematology through its bioinformatics tools and gene profiling technologies.

PLATFORM TECHNOLOGIES

- Gene profiling platform and biomarkers identification tools

Skuld-Tech engineered a gene profiling platform based on Non-Array methods (SAGE™, real time PCR,...) and a set of proprietary software. This platform offers two main benefits: the exhaustiveness of the outcomes and the network of users who share their gene profiles data. As of today, more than 600 gene profiles are made available to Skuld-Tech's clients and partners. The bioinformatics treatment and accurate analysis tools that are required to interpret the data have been developed by Skuld-Tech.

At the moment, this technological platform is unique when one look for the thorough study of all genes present in a single cell, and a precise identification and quantification. Moreover, Skuld-Tech platform can identify the genes involved in a disease whether these genes are known or not. For instance it has been determined that, in several physiopathological states, a limited number of genes (50 to 400 out of the whole genes present in the human genomics) are actually implicated in a given pathology.

- Transcriptomic libraries bioinformatics analysis

Skuld-Tech bioinformatics tools are essential to process and analyse transcriptomic libraries. These state of art investigation tools are covering experimental data and genomic tag identification, transcript comparison and threshold level signification expertise, gene expression annotation, data mining and gathering on a functional way all the non-array public available gene profiles.

y biomarkers of new therapies

- Development of Biomarkers data

From the transcriptome obtained with its gene profiling platform, Skuld-Tech has developed thematic biochips that allow a broader use of the data generated and most importantly a very high debit screening of various molecules in cellular culture studies. The impact of a molecule on a cell culture (induction of genes implicated in the inflammatory system or in a tumor process, precise identification of a cellular type) could be predict through these investigation tools.

Skuld-Tech proposes currently thematic DNA chips dedicated to leukemia and breast cancer.

DIAGNOSTIC TOOLS AND OTHER APPLICATIONS

Skuld-Tech has recently applied its technological platform and genomic strategy to identify gene expression changes associated with the use of the EPO stimulant.

EPO testing is now made possible by the combined use of Skuld-Tech/proprietary gene profiling libraries, transcriptomes of all blood cells and expression profiles of blood (from any spectrum of EPO agents use) developed at Skuld-Tech. This platform can be customized to fulfill your investigational needs.

The results of Skuld-Tech investigation platform such as EPO data libraries can be used to

- reposition molecules or drugs for other therapeutic indications,
- validate substitutes to old drug,
- discover new targets for existing or new molecules in diseases states associated with cell dysfunction such as blood cell lines for EPO,
- identif

Keywords	Diagnosis, antidoping, doping, blood, gene expression,		
Partners already involved	SIAB Pr. Michel Audran (Université Montpellier I) Pr Jacques Marti (Université Montpellier II)		
Project budget (for the running projects)	nc	Budget reserved for SMEs	nc

Research topics

- LSH-2005-1.2.1-3: Rational and accelerated development of new, safer, more effective drugs including pharmacogenomics approaches - STREPs dedicated to SMEs

- LSH-2005-1.2.2-4: Development of new diagnostics - STREPs dedicated to SMEs

- LSH-2005-1.2.5-4: Innovative research in post-genomics, which has high potential for application - STREPs dedicated to SMEs

- LSH-2005-2.2.0-7: Innovative technological approaches for cancer therapy - STREPs dedicated to SMEs

Profile of SME sought

Role	other
Country /region	any
Start of partnership	start-up phase
Expertise required	...

Project #115

Project #115 - Isil Kurnaz - Turkey

Date: 2005/07/06	Deadline: 2005/11/30
------------------	----------------------

Contact

Organisation	Isil Kurnaz	Department	Yeditepe University Dept. Genetics and Bioengineering
Contact person	Kurnaz, Ms. Isil		
Email	iakurnaz@yeditepe.edu.tr		
Address	26 Agustos Yerlesimi, Kayisdagi		
Postcode	34755	City	Istanbul
Country	Turkey		
Telephone	+905355764081	Fax	
Website			

Familiar with the European Framework Programme? **YES**

PROJECT

Title: Human stem cell approaches to neurodegenerative disorders	Acronym: NEUROSTEM
Project type	STREP
Status	Planned for submission
Call references	Call 4th

Priorities' Main Research Areas	gene expression profiling during neuronal differentiation of stem cells; identification of key transcription factors regulating each step of neuronal differentiation nervous tissue engineering potential applications to neuronal disorders		
Workprogramme Topic (according to each priority workprogramme)	microarray analysis of various stages of stem cell differentiation; clustering of co-regulated genes; functional genomic analysis of regulatory sites and identification of key transcriptional factors transcription factor-induced neuronal differentiation of stem cells nervous tissue engineering on 3-D biodegradable matrices		
Project description microarray analysis of various stages of stem cell differentiation; clustering of co-regulated genes; functional genomic analysis of regulatory sites and identification of key transcriptional factors transcription factor-induced neuronal differentiation of stem cells nervous tissue engineering on 3-D biodegradable matrices			
Keywords	neuronal differentiation, stem cell, nervous tissue engineering, bioinformatics		
Partners already involved			
Project budget (for the running projects)	nc	Budget reserved for SMEs	nc

Research topics

- LSH-2005-1.1.1-1: A systems approach to understanding the regulation of gene transcription - INTEGRATED PROJECT.

- LSH-2005-1.1.3-2: High throughput phenotyping tools and approaches for large scale functional genomics studies - INTEGRATED PROJECT.

- LSH-2005-1.2.2-1: High throughput molecular diagnostics for hereditary diseases - INTEGRATED PROJECT.

• LSH-2005-1.2.2-2: Development of innovative methods for diagnosis of nervous system disorders - STREP.

• LSH-2005-1.2.4-1: Tissue engineering approaches to treating children with birth defects - INTEGRATED PROJECT.

• LSH-2005-1.2.4-3: Stem Cell Therapy for Stroke Patients - STREP

• LSH-2005-1.2.4-5: Understanding monogenic rare diseases using insight from stem cell lines - STREP

• LSH-2005-2.1.1-7: Rare inherited neuromuscular disorders: from molecular basis to cutting edge therapies - NETWORK OF EXCELLENCE

• LSH-2005-2.1.3-6: Neuroscience-oriented new technologies - STREPs dedicated to SMEs

• LSH-2005-2.2.0-5: Exploring the patient's cancer stem cell as a novel therapeutic target - STREP

Profile of SME sought

Role	technology development, training
Country /region	Turkey
Start of partnership	start-up phase
Expertise required	bioinformatics, tissue engineering, biomaterial synthesis, stem cell technology

Project #116

Project #116 - Aurora Fine Chemicals Ltd - Austria

Date: 2005/07/11	Deadline: 2005/12/31
------------------	----------------------

Contact

Organisation	Aurora Fine Chemicals Ltd	Department	R&D
Contact person	Kutyrev, Mr Alexander		
Email	kutyrev@aurora-feinchemie.com		
Address	Reininghausstrasse 49		
Postcode	8020	City	Graz
Country	Austria		
Telephone	+43 316 586738	Fax	+43 316 584744
Website	http://www.aurora-feinchemie.com		

Familiar with the European Framework Programme? **YES**

PROJECT

Title: Design and development of a new active pharmaceutical ingredient	Acronym: New API
--	-------------------------

Project type	STREP
Status	Planned for submission
Call references	Call 4th

<p>Priorities' Main Research Areas</p>	<p>Advanced genomics and its application for health / - Application of knowledge and technologies in the field of genomics and biotechnology for health</p> <p>Combating major diseases / - Applications-orientated genomic approaches to medical knowledge and technologies - Combating cancer - Confronting the major communicable diseases linked to poverty</p>
<p>Workprogramme Topic (according to each priority workprogramme)</p>	<p>LSH-2005-1.2.1-3: Rational and accelerated development of new, safer, more effective drugs including pharmacogenomics approaches - STREPs dedicated to SMEs</p> <p>LSH-2005-1.2.4-7: Development and testing of new preventive and therapeutic tools, such as somatic gene and cell therapies (in particular stem cell therapies) and immunotherapies – STREPs dedicated to SMEs</p> <p>LSH-2005-1.2.5-3: Use of cell lines to define new bioassays for the identification of therapeutic bio-molecules (especially orientated towards small and medium sized companies) - STREP</p> <p>LSH-2005-2.1.1-7: Rare inherited neuromuscular disorders: from molecular basis to cutting edge therapies - NETWORK OF EXCELLENCE</p> <p>LSH-2005-2.1.3-8: Early markers and new targets for neurodegenerative diseases - STREPs dedicated to SMEs</p> <p>LSH-2005-2.2.0-8: Small-ligand libraries: improved tools for exploration and prospective anti-tumor therapy - STREPs dedicated to SMEs</p> <p>LSH-2005-2.2.0-8: Small-ligand libraries: improved tools for exploration and prospective anti-tumor therapy - STREPs dedicated to SMEs</p>

Project description

Our company synthesizes chemical organical compounds, so called small molecules for biological research and development. Over the 10-years business in the field of custom synthesis and custom research we collected experience, marketing knowledge and compounds library with more than 31,000 available from stock structures. We would like to set this substances collection as a base for one or more projects where the targets (biologicals systems from proteins to cells) should be tested on their activity with our compounds. The results of this screening provide the active structures that will be the headstone for further synthesis and screening thereafter the lead structure can be obtained. This lead is our object.

The project process is to see on the following scheme:

1. Identification of target (biological system from molecule to cell).
2. Computer modelling of target active (blocked or activated depends on target) small molecules.
3. Synthesis and screening of small molecules.
4. design and development of lead.

P.1 on the scheme takes the potential partner who are able to recognize and identify the targets. The kind of targets is not important for us.

P.2 on the scheme takes the potential computer modelling partner.

P.3 and P.4 (synthesis and development) takes our company.

P.3 and P.4 (screening and design) take partner with screening facilities and computer modelling partner.

Keywords	API, target, lead, screening, computer modelling, compounds library, drug design		
Partners already involved			
Project budget (for the running projects)	nc	Budget reserved for SMEs	nc

Research topics

- LSH-2005-1.2.1-3: Rational and accelerated development of new, safer, more effective drugs including pharmacogenomics approaches - STREPs dedicated to SMEs

- LSH-2005-1.2.4-7: Development and testing of new preventive and therapeutic tools, such as somatic gene and cell therapies (in particular stem cell therapies) and immunotherapies – STREPs dedicated to SMEs

- LSH-2005-1.2.5-3: Use of cell lines to define new bioassays for the identification of therapeutic bio-molecules (especially orientated towards small and medium sized companies) - STREP

- LSH-2005-2.1.1-7: Rare inherited neuromuscular disorders: from molecular basis to cutting edge therapies - NETWORK OF EXCELLENCE

- LSH-2005-2.1.3-8: Early markers and new targets for neurodegenerative diseases - STREPs dedicated to SMEs

- LSH-2005-2.2.0-8: Small-ligand libraries: improved tools for exploration and prospective anti-tumor therapy - STREPs dedicated to SMEs

- LSH-2005-2.3.0-4: New approaches for research into host/vector-pathogen interaction for HIV/AIDS, malaria and tuberculosis - STREP

Profile of SME sought

Role	technology development, research, dissemination
Country /region	all countries
Start of partnership	start-up phase

**Expertise
required**

The project process is to see on the following scheme:

1. Identification of target (biological system from molecule to cell).

2. Computer modelling of target active (blocked or activated depends on target) small molecules.

3. Synthesis and screening of small molecules.

4. design and development of lead.

P.1 on the scheme takes the potential partner who are able to recognize and identify the targets. The kind of targets is not important for us.

P.2 on the scheme takes the potential computer modelling partner.

P.3 and P.4 (synthesis and development) takes our company.

P.3 and P.4 (screening and design) take partner with screening facilities and computer modelling partner.